Oxford Astrazeneca Covid-19 Vaccine
- All
- News
- Videos
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
AstraZeneca Tests Booster Vaccine Against Beta Variant Of Covid
AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
Indian Medical Experts Support Call For Covishield Vaccine Safety Review
A number of Indian medical experts on Monday supported calls from an eminent British Indian cardiologist for a full safety review into the use of the Oxford/AstraZeneca's COVID-19 vaccine, administered in India as Covishield.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
On Omicron, AstraZeneca Says Booster Effective, Cites Oxford Lab Study
A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
-
Next Virus Could Be More Lethal, Warns Oxford University Covid Vaccine Creator
The scientist behind the creation of the Oxford/AstraZeneca vaccine, administered in India as Covishield to protect against COVID-19, on Monday warned that the next virus to hit humankind may be even more lethal and contagious.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
Protection From Pfizer, AstraZeneca Jabs Wanes Within 6 Months: UK Study
Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.
-
Pfizer Jab Effectiveness "Declines Faster" Than AstraZeneca: Oxford Study
The effectiveness of the Pfizer-BioNTech vaccine against Covid-19 declines faster than that of the AstraZeneca jab, according to a new study published on Thursday.
-
Clotting From Covid Shots Is Rare But "Potentially Devastating": Study
Researchers say they're making progress in understanding a clotting disorder linked to Covid-19 vaccines that they describe as very rare but potentially "devastating."
-
Astra Jab Followed By Pfizer, 4 Weeks Apart, Gives Strong Immunity: Study
Mixing doses of Covid-19 vaccines from Pfizer Inc. and AstraZeneca Plc creates a strong immune response, according to results from a University of Oxford study, a finding that could enable greater flexibility in the use of scarce supplies.
-
Third AstraZeneca Shot, 6 Months After Second, Works Great: Study
Delayed second and third doses of the AstraZeneca vaccine boost immunity against COVID-19, a study by Oxford University, which developed the jab with the British-Swedish firm, said on Monday.
-
AstraZeneca Tests Booster Vaccine Against Beta Variant Of Covid
AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa.
-
Two Doses Mostly Prevent Hospitalisation With Delta Variant: UK Body
Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.
-
Britain Seeks Extra AstraZeneca Shots To Combat "Beta" COVID-19 Variant
Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.
